Imaging software developer Definiens has announced the release of its quantitative digital pathology portfolio designed to advance translational research in pathology, specifically biomarker development.
The new portfolio includes Definiens Image Miner and updated versions of Tissue Studio and Developer XD. This product range is designed to provide high accuracy in automatically identifying relevant structures of interest and specific morphology in histology, resulting in a detailed phenotypic fingerprint and biomarker expression provided on a cell-by-cell basis. The large set of descriptors can be correlated against therapy response or patient outcome, with the goal of identifying new types of biomarkers of predictive or prognostic value, according to the company.
Definiens Image Miner 1 integrates data mining with image analysis to accelerate biomarker research. The new product is designed to provide a substantial productivity increase when profiling tissue probes for clinically or diagnostically relevant differences in morphology or biomarker expression. Development and quality control are supported by links between data points and visual inspections of associated regions in the tissue.
Definiens Tissue Studio 3, an updated version of the company's image analysis solution for quantitative digital pathology, combines quantification of tissue specimens with a rapid configuration workflow. New features include improved detection of regions of interest, classification of nuclear morphology, and an angiogenesis module.
